Detalles de la búsqueda
1.
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
Ann Oncol
; 2024 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38834388
2.
Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
Br J Cancer
; 129(9): 1373-1382, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37524968
3.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Ann Oncol
; 34(4): 389-396, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709039
4.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Ann Oncol
; 33(4): 434-444, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35066105
5.
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Ann Oncol
; 33(10): 1041-1051, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850444
6.
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Cancer Immunol Immunother
; 71(12): 2985-2998, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35596791
7.
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Ann Oncol
; 32(9): 1101-1110, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34089836
8.
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Ann Oncol
; 31(11): 1491-1505, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32853681
9.
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Ann Oncol
; 31(2): 289-294, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31959346
10.
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Ann Oncol
; 30(12): 1985-1991, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31584608
11.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Ann Oncol
; 30(8): 1321-1328, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125062
12.
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Ann Oncol
; 29(4): 959-965, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29408986
13.
Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
J Clin Pharm Ther
; 43(3): 320-326, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29092096
14.
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
Br J Cancer
; 116(3): 344-348, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081545
15.
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges.
Ann Oncol
; 33(1): 6-12, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34655734
16.
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Ann Oncol
; 28(9): 2241-2247, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28911085
17.
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Ann Oncol
; 28(11): 2715-2724, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945865
18.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Ann Oncol
; 28(5): 1078-1083, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327934
19.
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Ann Oncol
; 33(12): 1328-1331, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36122799
20.
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Ann Oncol
; 27(2): 281-6, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26598547